MANAGEMENT OF RESISTANT HYPERTENSION AND IMPLICATIONS OF PATHWAY-2 TRIAL IN US CARDIOLOGY PRACTICE: INSIGHTS FROM THE NCDR PINNACLE REGISTRY

Patients with resistant hypertension (rHTN) have uncontrolled hypertension despite receiving at least 3 anti-HTN medication classes. The recent PATHWAY-2 Trial demonstrated superior HTN control when spironolactone was added as a 4th agent in rHTN. However, the applicability of PATHWAY-2 in